The present disclosure provides a bio-material composition and method of use in craniomaxillofacial surgery. An example method comprises: accessing a space defined between adjacent bone structures in a head of a patient; mixing magnesia, potassium biphosphate, and a calcium phosphate with an aqueous solution to form an activated bone fusion slurry (ABFS); applying an effective amount of the ABFS to the space between the adjacent bone structures; allowing the ABFS to set forming a bonded bone structure; and permitting bone growth into the bonded bone structure providing fusion of the two adjacent bone structures, wherein the ABFS promotes fusion of the two adjacent bone structures without the need for additional physical fixation devices.

The present disclosure provides a bio-material composition and method of use in craniomaxillofacial surgery. An example method comprises: accessing a space defined between adjacent bone structures in a head of a patient; mixing magnesia, potassium biphosphate, and a calcium phosphate with an aqueous solution to form an activated bone fusion slurry (ABFS); applying an effective amount of the ABFS to the space between the adjacent bone structures; allowing the ABFS to set forming a bonded bone structure; and permitting bone growth into the bonded bone structure providing fusion of the two adjacent bone structures, wherein the ABFS promotes fusion of the two adjacent bone structures without the need for additional physical fixation devices.

Disclosed herein are composition and methods of treating a condition where enhanced immunogenicity is desired. Some embodiments disclosed herein relate to compositions comprising a T-cell activator and/or proliferator, one or more immune checkpoint inhibitor, and a FPPS inhibitor. Some embodiments relate to methods of treating cancer by co-administering plinabulin, one or more immune checkpoint inhibitor, and a FPPS inhibitor to a subject in need thereof.

Disclosed herein are composition and methods of treating a condition where enhanced immunogenicity is desired. Some embodiments disclosed herein relate to compositions comprising a T-cell activator and/or proliferator, one or more immune checkpoint inhibitor, and a FPPS inhibitor. Some embodiments relate to methods of treating cancer by co-administering plinabulin, one or more immune checkpoint inhibitor, and a FPPS inhibitor to a subject in need thereof.

Disclosed herein are composition and methods of treating a condition where enhanced immunogenicity is desired. Some embodiments disclosed herein relate to compositions comprising a T-cell activator and/or proliferator, one or more immune checkpoint inhibitor, and a FPPS inhibitor. Some embodiments relate to methods of treating cancer by co-administering plinabulin, one or more immune checkpoint inhibitor, and a FPPS inhibitor to a subject in need thereof.

The present invention provides a composition for relief or management of a pain associated with a disorder, e.g., joint or skeletal condition, the composition comprises n effective amount of retinoic acid. Methods of making and using the same are also disclosed.

The present invention provides a composition for relief or management of a pain associated with a disorder, e.g., joint or skeletal condition, the composition comprises n effective amount of retinoic acid. Methods of making and using the same are also disclosed.

A composition that achieves sustained oral drug release is provided. The composition includes liposomes, micelles, or polymeric particles, for example, having a hydrophobic core and an amphipathic corona, wherein the core contains a therapeutic, diagnostic, nutraceutical, cosmeceutical or prophylactic agent to be released, and the corona has targeting ligands immobilized to it. In a preferred embodiment the targeting ligands are bisphosphonate molecules, which enable binding to hydroxyapatite present on teeth. The incorporation of short polyethylene glycol (PEG) chains prevents chain entanglement and ionic interactions, minimizes mucus adhesion, increases particle diffusion rates in mucus, and increases the overall stability of particles in saliva. In a preferred embodiment the agent incorporated is a dental bleaching agent and the ligands selectively bind hydroxyapatite.

A composition that achieves sustained oral drug release is provided. The composition includes liposomes, micelles, or polymeric particles, for example, having a hydrophobic core and an amphipathic corona, wherein the core contains a therapeutic, diagnostic, nutraceutical, cosmeceutical or prophylactic agent to be released, and the corona has targeting ligands immobilized to it. In a preferred embodiment the targeting ligands are bisphosphonate molecules, which enable binding to hydroxyapatite present on teeth. The incorporation of short polyethylene glycol (PEG) chains prevents chain entanglement and ionic interactions, minimizes mucus adhesion, increases particle diffusion rates in mucus, and increases the overall stability of particles in saliva. In a preferred embodiment the agent incorporated is a dental bleaching agent and the ligands selectively bind hydroxyapatite.

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.